ライフサイエンスコーパス: residual cancer

1 ne the resection bed in vivo for microscopic residual cancer.

2 on halting progression in models of minimal residual cancer.

3 was elevated in 24 of 36 (67%) patients with residual cancer; 201Tl detected tumor sites in 13 of 24

4 were predicted to have residual disease had residual cancer (27 of 28 patients).

5 Assessment for residual cancer after chemoradiation is still problemati

6 However, many patients have residual cancer after chemotherapy, which correlates wit

7 L-12 protected against growth of microscopic residual cancer after hepatic resection.

8 Forty-seven consecutive patients with residual cancer after resection of PMNSGCT were retrospe

9 chived tumors of limited sample size such as residual cancer after treatment or metastatic biopsies.

10 and may be responsible for the existence of residual cancer after treatment.

11 e assessment of the presence and location of residual cancer after unsuccessful therapy and helped id

12 However, the molecular patterns of the residual cancers after 3 months of docetaxel treatment w

13 Of the 12 patients who had residual cancer and false-negative serum Tg levels, 6 ha

14 l margin, and furthermore detected extensive residual cancer at the circumferential margin in a case

15 Pathologic response was quantified using the residual cancer burden (RCB) method.

16 Residual cancer burden (RCB) was calculated as a continu

17 ompared with association of RFS with PCR and residual cancer burden (RCB), while controlling for age,

18 edict pathologic complete response (pCR) and residual cancer burden (RCB).

19 urvival, pathological complete response, and residual cancer burden in the Nottingham discovery cohor

20 o distinguish inflammation and fibrosis from residual cancer, but a more than 50% decrease in tumor c

21 In mouse models, between 3 and 30 residual cancer cells and MRD (undetectable with current

22 g that they must have harbored low levels of residual cancer cells at the end of therapy.

23 lignancy effect, that is, the recognition of residual cancer cells by the T cells of the donor, is a

24 ranscriptomic and histological signatures of residual cancer cells from neoadjuvant-treated breast ca

25 partial response (pathPR) rate of 15% (< 10% residual cancer cells in the resected specimen).

26 Surgery guided by ACPPD resulted in fewer residual cancer cells left in the animal after surgery a

27 a and can promote the growth and survival of residual cancer cells to foster tumor recurrence and met

28 peutic strategies are necessary to eradicate residual cancer cells to prevent disease recurrence.

29 d for novel therapeutics that can target the residual cancer cells whose phenotypes are distinct from

30 esponse (pathologic complete response or <5% residual cancer cells) were evaluated using logistic reg

31 s were as follows: 75% complete response (no residual cancer cells), 56% major response (1% to 49% re

32 cancer cells), 56% major response (1% to 49% residual cancer cells), and 33% minor response (> or = 5

33 5 (33%) had specimens that had less than 5% residual cancer cells, and 2 (13%) had specimens that ha

34 fers a potentially powerful new way to clear residual cancer cells, showing how restoring immune surv

35 GVM by transfer of active oncolytic virus to residual cancer cells.

36 se may enhance tumor progression features of residual cancer cells.

37 is an appealing approach to induce death of residual cancer cells.

38 were capable of trafficking to and targeting residual cancer cells.

39 r cells), and 33% minor response (> or = 50% residual cancer cells; complete v major response, P = .0

40 Although residual cancer following preoperative CMT was more like

41 Planar images missed residual cancer in high cervical lymph nodes adjacent to

42 Both imaging agents detected residual cancer in more than half of the patients in who

43 ay be useful for intraoperative detection of residual cancer in surgical tumor margins.

44 ological complete response (i.e., absence of residual cancer in the breast or lymph nodes at the time

45 tomy increases the likelihood of eliminating residual cancer in the cystectomy specimen and is associ

46 survival was associated with the absence of residual cancer in the cystectomy specimen.

47 Postchemotherapy surgical resection of residual cancer may result in 5-year disease-free surviv

48 e risk is mostly associated with presence of residual cancer on explant.

49 , and to determine feasibility for detecting residual cancer on tumor resection margins, using a gene

50 stance mechanisms underlying the survival of residual cancer 'persister' cells.

51 Seven (78%) of nine patients had no residual cancer; specimens contained fat necrosis.

52 is may be an effective strategy to eradicate residual cancer stem cells that are otherwise resistant

53 al ovarian cancer and may be attributable to residual cancer stem cells, or cancer-initiating cells,

54 to delay tumor progression by reprogramming residual cancer stem-like cells.

55 ed for the rapid intraoperative detection of residual cancer tissue during breast-conserving surgery.

56 guish them from the features of recurrent or residual cancer to aid subsequent clinical management.

57 The longest dimension of the residual cancer was measured at MR imaging and correlate